Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome

Haematologica

Volumn 102, Issue 12, 2017, Pages 2021-2029

  Singhal, Deepak ^a,b,c   Kutyna, Monika M ^b   Chhetri, Rakchha ^b   Wee, Li Yan A ^b   Hague, Sophia ^d   Nath, Lakshmi ^e   Nath, Shriram V ^e,f   Sinha, Romi ^g   Wickham, Nicholas ^f   Lewis, Ian D ^a,b,c   Ross, David M ^a,b,c,h,i   Bardy, Peter G ^a,b,c   To, Luen Bik ^a,b,c   Reynolds, John ^j   Wood, Erica M ^j   Roxby, David J ^d,h   Hiwase, Devendra K ^a,b,c,i  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b Haematology Department   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Transfusion Medicine   (Australia)

^e Clinpath Laboratories   (Australia)

^f Ashford Cancer Centre   (Australia)

^g SA Health   (Australia)

^h FLINDERS UNIVERSITY   (Australia)

ⁱ SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^j MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY;

ADULT; AGED; ALLOIMMUNIZATION; ARTICLE; BLOOD TRANSFUSION REACTION; CHRONIC LYMPHATIC LEUKEMIA; ERYTHROCYTE TRANSFUSION; FEMALE; HEART ARREST; HEMOLYSIS; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; RISK FACTOR; AUSTRALIA; BIOSYNTHESIS; BLOOD; ERYTHROCYTE; IMMUNOLOGY; METABOLISM;

AGED; AUSTRALIA; AUTOANTIBODIES; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; ISOANTIBODIES; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 85037034902     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.175752     Document Type: Article

References (36)

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
2. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon: International Agency for Research on Cancer; 2008. p. 88-93.
3. Visser O, Trama A, Maynadie M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17):3257-3266.
4. Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood. 2014;123(6):829-836.
5. Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013; 121(21):4280-4286.
6. Hellstrom-Lindberg E. Management of anemia associated with myelodysplastic syndrome. Semin Hematol. 2005;42(2 Suppl 1):S10-13.
7. Hiwase DK, Singhal D, Strupp C, et al. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. Am J Hematol. 2017;92(6):508-514.
8. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
9. FDA. Fatalities Reported to FDA Following Blood Collection and Transfusion. US Department of Health and Human Services. [cited 2017 August 20]. Available from: https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities.
10. Telen MJ, Afenyi-Annan A, Garrett ME, et al. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion. 2015;55(6 pt2):1378-1387.
11. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion. 2016;56(1):107-114.
12. Young PP, Uzieblo A, Trulock E, et al. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion. 2004;44(1):67-72.
13. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoim-munization in transfusion-dependent tha-lassemia patients of predominantly Asian descent. Blood. 2000;96(10):3369-3373.
14. Castellino SM, Combs MR, Zimmerman SA, et al. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol. 1999;104(1):189-194.
15. Garratty G. Autoantibodies induced by blood transfusion. Transfusion. 2004;44 (1):5-9.
16. Aygun B, Padmanabhan S, Paley C, et al. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42(1):37-43.
17. Ahrens N, Pruss A, Kahne A, et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion. 2007;47(5):813-816.
18. Stiegler G, Sperr W, Lorber C, et al. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol. 2001;80(6):330-333.
19. Sanz C, Nomdedeu M, Belkaid M, et al. Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Transfusion. 2013;53(4):710-715.
20. Novaretti MC, Sopelete CR, Velloso ER, et al. Immunohematological findings in myelodysplastic syndrome. Acta Haematol. 2001;105(1):1-6.
21. Winters JL, Richa EM, Bryant SC, et al. Polyethylene glycol antiglobulin tube versus gel microcolumn: influence on the incidence of delayed hemolytic transfusion reactions and delayed serologic transfusion reactions. Transfusion. 2010;50(7):1444-1452.
22. Vamvakas EC, Pineda AA, Reisner R, et al. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis. Transfusion. 1995;35(1):26-32.
23. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39(7):763-771.
24. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol. 1995;91(4):1000-1005.
25. Evers D, Zwaginga JJ, Tijmensen J, et al. Treatments for hematological malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. Haematologica. 2016;102(1):52-59.
26. Evers D, Middelburg RA, de Haas M, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3(6):e284-e292.
27. Guelsin GA, Rodrigues C, Visentainer JE, et al. Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome. Blood Transfus. 2015;13(1):53-58.
28. Ortiz S, Orero MT, Javier K, et al. Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome. Blood Transfus. 2017;15(5):472-477.
29. Rozovski U, Ben-Tal O, Kirgner I, et al. Increased incidence of red blood cell alloantibodies in myelodysplastic syndrome. Isr Med Assoc J. 2015;17(10): 624-627.
30. Lin Y, Saskin A, Wells RA, et al. Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion-dependent patients with myelodysplastic syndromes. Vox Sang. 2017;112(1):79-86.
31. Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang. 2014;106(3):197-208.
32. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sick- le cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990;76(7): 1431-1437.
33. Kordasti SY, Afzali B, Lim Z, et al. IL-17-pro-ducing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145(1):64-72.
34. Kotsianidis I, Bouchliou I, Nakou E, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia. 2009;23(3):510-518.
35. Kaminski ER, Hows JM, Goldman JM, et al. Lymphocytes from multi-transfused patients exhibit cytotoxicity against autologous cells. Br J Haematol. 1992;81(1):23-26.
36. Flegel WA, Gottschall JL, Denomme GA. Integration of red cell genotyping into the blood supply chain: a population-based study. Lancet Haematol. 2015;2(7):e282-e289.